| Year |
Citation |
Score |
| 2023 |
Webb MJ, Kottke T, Kendall BL, Swanson J, Uzendu C, Tonne J, Thompson J, Metko M, Moore M, Borad M, Roberts L, Diaz RM, Olin M, Borgatti A, Vile R. Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses. Molecular Therapy Oncolytics. 29: 129-142. PMID 37313455 DOI: 10.1016/j.omto.2023.05.006 |
0.353 |
|
| 2022 |
Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, McClellan BL, Varela ML, Stamatovic SM, Martinez-Revollar G, Andjelkovic AV, Gregory JV, Kadiyala P, Calinescu A, Jiménez JA, ... ... Olin MR, et al. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy. Acs Nano. PMID 35616289 DOI: 10.1021/acsnano.1c07492 |
0.316 |
|
| 2021 |
Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, et al. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T-cell response in low-grade gliomas. The Journal of Clinical Investigation. PMID 34882581 DOI: 10.1172/JCI151239 |
0.349 |
|
| 2021 |
Alghamri MS, McClellan BL, Hartlage MS, Haase S, Faisal SM, Thalla R, Dabaja A, Banerjee K, Carney SV, Mujeeb AA, Olin MR, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Frontiers in Pharmacology. 12: 680021. PMID 34084145 DOI: 10.3389/fphar.2021.680021 |
0.307 |
|
| 2021 |
Ampudia-Mesias E, Puerta-Martinez F, Bridges M, Zellmer D, Janeiro A, Strokes M, Sham YY, Taher A, Castro MG, Moertel CL, Pluhar GE, Olin MR. CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33829411 DOI: 10.1007/s13311-021-01038-1 |
0.325 |
|
| 2019 |
Xiong Z, Ampudia Mesias E, Pluhar GE, Rathe SK, Largaespada DA, Sham YY, Moertel CL, Olin MR. CD200 Checkpoint Reversal:A Novel Approach to Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31624103 DOI: 10.1158/1078-0432.Ccr-19-2234 |
0.492 |
|
| 2019 |
Olin MR, Ampudia-Mesias E, Pennell CA, Sarver A, Chen CC, Moertel CL, Hunt MA, Pluhar GE. Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma. Cancers. 11. PMID 30682795 DOI: 10.3390/Cancers11020137 |
0.534 |
|
| 2019 |
Moertel C, Pluhar GE, Ampudia-Mesias E, Xiong Z, Pennell CA, Rathe SK, Largaespada DA, Olin MR. IMMU-23. TARGETING THE CD200 CHECKPOINT TO ENHANCE IMMUNOTHERAPY FOR CNS TUMORS Neuro-Oncology. 21: ii97-ii98. DOI: 10.1093/Neuonc/Noz036.142 |
0.455 |
|
| 2018 |
Olin M, Ampudia-Mesias E, Pennell CA, Xiong Z, Rathe SK, Largaespada DA, Moertel CL, Pluhar GE. CADD-14. TARGETING THE CD200 CHECKPOINT FOR THE FIGHT AGAINST CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 20: vi278-vi279. DOI: 10.1093/Neuonc/Noy148.1159 |
0.444 |
|
| 2018 |
Pluhar E, Ampudia-Mesias E, Xiong Z, Moertel C, Olin M. Immu-03. Targeting The Cd200 Checkpoint Blockade For The Fight Against Central Nervous System Tumors Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.319 |
0.445 |
|
| 2017 |
Ampudia-Mesias E, Moertel C, Pluhar E, Olin M. Immu-14. Targeting Cd200 Activation Receptors To Overcome The Immunosuppressive Tumor Microenvironment Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.473 |
0.433 |
|
| 2017 |
Olin M, Ampudia-Mesias E, Xiong Z, Pluhar E, Moertel C. Immu-11. Targeting The Cd200 Checkpoint Blockade: A New Direction For Immunotherapy Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.470 |
0.367 |
|
| 2017 |
Pluhar E, Olin M, Hunt M. Tmod-25. Peptides Of Immune Checkpoint Protein, Cd200 (Ox2), Enhances The Response To Vaccine-Based Immunotherapy In Dogs With High-Grade Glioma Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.1062 |
0.44 |
|
| 2017 |
Ampudia-Mesias E, Moertel C, Olin M. Immu-02. Targeting Cd200 Activation Receptors To Overcome The Immunosuppressive Tumor Microenvironment: A New Direction For Checkpoint Immunotherapy Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox083.113 |
0.441 |
|
| 2016 |
Xiong Z, Ampudia-Mesias E, Shaver R, Horbinski CM, Moertel CL, Olin MR. Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy. Immunotherapy. 8: 1059-71. PMID 27485078 DOI: 10.2217/Imt-2016-0033 |
0.521 |
|
| 2016 |
Moertel C, Pluhar E, Olin M. Tb-01Cd200 Checkpoint Blockade Plays An Important Role In Cns Tumor Immunoediting Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now084.01 |
0.413 |
|
| 2015 |
Pluhar GE, Pennell CA, Olin MR. CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity. Critical Reviews in Immunology. 35: 153-72. PMID 26351148 DOI: 10.1615/Critrevimmunol.2015013607 |
0.507 |
|
| 2015 |
Pluhar GE, Pennell CA, Olin MR. CD8<sup>+</sup> T cell–independent immune-mediated mechanisms of anti-tumor activity Critical Reviews in Immunology. 35: 153-172. DOI: 10.1615/CritRevImmunol.2015013607 |
0.43 |
|
| 2015 |
Mesias E, Xiong Z, Pluhar E, Olin M. Use of CD200 blockade inhibitor to enhance glioma immunotherapy Journal For Immunotherapy of Cancer. 3: 38. DOI: 10.1186/2051-1426-3-S2-P38 |
0.506 |
|
| 2015 |
Gustafson M, Deeds M, Maas M, Peterson T, Lin Y, Olin M, Gastineau D, Parney I, Dietz A. Using comprehensive immune profiles to identify glioblastoma patients responsive to autologous dendritic cell vaccines Cytotherapy. 17. DOI: 10.1016/J.Jcyt.2015.03.359 |
0.387 |
|
| 2014 |
Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. Journal For Immunotherapy of Cancer. 2: 46. PMID 25598973 DOI: 10.1186/S40425-014-0046-9 |
0.477 |
|
| 2014 |
Olin MR, Pluhar GE, Andersen BM, Shaver R, Waldron NN, Moertel CL. Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Critical Reviews in Immunology. 34: 399-432. PMID 25404047 DOI: 10.1615/Critrevimmunol.2014011577 |
0.477 |
|
| 2014 |
Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, Blazar B, Ohlfest JR, Moertel C. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. Journal For Immunotherapy of Cancer. 2: 4. PMID 24829761 DOI: 10.1186/2051-1426-2-4 |
0.471 |
|
| 2014 |
Pluhar L, Olin M, Goulart M, Andersen B, Hunt M, Ohlfest J. PM-17INTRACEREBRAL IFN-γ DOES NOT ENHANCE THE RESPONSE TO VACCINE IMMUNOTHERAPY FOR CANINE GLIOMA Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou268.17 |
0.462 |
|
| 2014 |
Pluhar L, Goulart M, Seiler C, Olin M. Pm-16Immunosuppressive Factors, Mdsc And Arginase, Are Elevated In Dogs With Malignant Glioma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou268.16 |
0.331 |
|
| 2013 |
Swaminathan SK, Niu L, Waldron N, Kalscheuer S, Zellmer DM, Olin MR, Ohlfest JR, Vallera DA, Panyam J. Identification and characterization of a novel scFv recognizing human and mouse CD133. Drug Delivery and Translational Research. 3: 143-51. PMID 25787982 DOI: 10.1007/S13346-012-0099-6 |
0.398 |
|
| 2013 |
Andersen BM, Pluhar GE, Seiler CE, Goulart MR, SantaCruz KS, Schutten MM, Meints JP, O'Sullivan MG, Bentley RT, Packer RA, Thomovsky SA, Chen AV, Faissler D, Chen W, Hunt MA, ... Olin MR, et al. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Research. 73: 2987-97. PMID 23471847 DOI: 10.1158/0008-5472.Can-12-3366 |
0.461 |
|
| 2013 |
Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, Salazar AM, Olin MR. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. Journal of Immunology (Baltimore, Md. : 1950). 190: 613-20. PMID 23248259 DOI: 10.4049/Jimmunol.1201557 |
0.487 |
|
| 2013 |
Moertel C, Xi J, Olin MR. Understanding and overcoming the immunosuppressive effects of glioma induced immunosuppression Journal For Immunotherapy of Cancer. 1: 169. DOI: 10.1186/2051-1426-1-S1-P169 |
0.509 |
|
| 2012 |
Murphy KA, Lechner MG, Popescu FE, Bedi J, Decker SA, Hu P, Erickson JR, O'Sullivan MG, Swier L, Salazar AM, Olin MR, Epstein AL, Ohlfest JR. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4657-68. PMID 22781551 DOI: 10.1158/1078-0432.Ccr-12-0990 |
0.391 |
|
| 2012 |
Moertel CL, Olin M, Dahlheimer T, Gustafson M, Sumstand D, McKenna D, Low W, Nascene D, Dietz A, Ohlfest J. Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells. Journal of Clinical Oncology. 30: 2546-2546. DOI: 10.1200/Jco.2012.30.15_Suppl.2546 |
0.378 |
|
| 2011 |
Olin MR, Andersen BM, Litterman AJ, Grogan PT, Sarver AL, Robertson PT, Liang X, Chen W, Parney IF, Hunt MA, Blazar BR, Ohlfest JR. Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Research. 71: 6583-9. PMID 21908554 DOI: 10.1158/0008-5472.Can-11-1166 |
0.473 |
|
| 2011 |
Olin M, Choi K, Molitor TW. Morphine alters M. bovis infected microglia's ability to activate γδ T lymphocytes. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 6: 578-84. PMID 21881858 DOI: 10.1007/S11481-011-9308-1 |
0.32 |
|
| 2010 |
Olin MR, Andersen BM, Zellmer DM, Grogan PT, Popescu FE, Xiong Z, Forster CL, Seiler C, SantaCruz KS, Chen W, Blazar BR, Ohlfest JR. Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4800-8. PMID 20858839 DOI: 10.1158/1078-0432.Ccr-10-1572 |
0.414 |
|
| 2010 |
Swaminathan SK, Olin MR, Forster CL, Cruz KS, Panyam J, Ohlfest JR. Identification of a novel monoclonal antibody recognizing CD133. Journal of Immunological Methods. 361: 110-5. PMID 20674577 DOI: 10.1016/J.Jim.2010.07.007 |
0.384 |
|
| 2010 |
Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine. 28: 3371-8. PMID 20197146 DOI: 10.1016/J.Vaccine.2010.02.082 |
0.46 |
|
| 2007 |
Griffin RJ, Williams BW, Bischof JC, Olin M, Johnson GL, Lee BW. Use of a fluorescently labeled poly-caspase inhibitor for in vivo detection of apoptosis related to vascular-targeting agent arsenic trioxide for cancer therapy. Technology in Cancer Research & Treatment. 6: 651-4. PMID 17994796 DOI: 10.1177/153303460700600609 |
0.336 |
|
| 2007 |
Olin MR, Choi K, Lee J, Peterson PK, Molitor TW. Morphine modulates gammadelta lymphocytes cytolytic activity following BCG vaccination. Brain, Behavior, and Immunity. 21: 195-201. PMID 16870392 DOI: 10.1016/J.Bbi.2006.06.003 |
0.393 |
|
| 2005 |
Olin MR, Hwa Choi K, Lee J, Molitor TW. Gammadelta T-lymphocyte cytotoxic activity against Mycobacterium bovis analyzed by flow cytometry. Journal of Immunological Methods. 297: 1-11. PMID 15777926 DOI: 10.1016/J.Jim.2004.10.002 |
0.388 |
|
| 2004 |
Lõhmus M, Olin M, Sundström LF, Troedsson MH, Molitor TW, El Halawani M. Leptin increases T-cell immune response in birds. General and Comparative Endocrinology. 139: 245-50. PMID 15560871 DOI: 10.1016/J.Ygcen.2004.09.011 |
0.312 |
|
| 2004 |
Lee J, Choi K, Olin MR, Cho SN, Molitor TW. Gammadelta T cells in immunity induced by Mycobacterium bovis bacillus Calmette-Guérin vaccination. Infection and Immunity. 72: 1504-11. PMID 14977956 DOI: 10.1128/Iai.72.3.1504-1511.2004 |
0.422 |
|
| Show low-probability matches. |